Table 3. Response and clinical outcome.
| Clinical features | CR n (%) | Median OS (months) | Median DFS (months) | 1-year OS (%) | 2-year OS (%) |
| All patients (n=125) | 94 (75.2) | 16 | 12 | 59.8 | 36.5 |
| Age (years) | P=0.5473 | P=0.0070 | P=0.1220 | ||
| 60-66 (n=65) | 51 (78.5) | 19 | 15 | 70.6 | 45.1 |
| 67-74 (n=39) | 29 (74.4) | 14 | 11 | 53.2 | 36.6 |
| 75-86 (n=21) | 14 (66.7) | 9 | 7 | 40.6 | 20.3 |
| Patients aged 60-66 years (n=65) | P=0.3612 | P=0.0134 | P=0.4344 | ||
| Low- and intermediate-risk (n=37) | 31 (83.8) | 28 | 15 | 84.0 | 53.7 |
| High-risk (n=28) | 20 (71.4) | 13 | 14 | 52.8 | 35.2 |
| Patients aged 67-74 years (n=39) | P=1.0000 | P=0.0681 | P=0.0014 | ||
| Low- and intermediate-risk (n=17) | 13 (76.5) | 32 | 19 | 69.0 | 40.0 |
| High-risk (n=22) | 16 (72.7) | 12 | 6 | 52.6 | 22.8 |
| Patients aged 75-86 years (n=21) | P=0.6557 | P=0.2110 | P=0.1048 | ||
| Low- and intermediate-risk (n=8) | 6 (75.0) | 18 | 13 | 19.4 | N/A |
| High-risk (n=13) | 8 (61.5) | 9 | 6 | 10.3 | N/A |
| Numbers of mutations | P=0.0035 | P=0.1570 | P=0.6556 | ||
| 0-1 (n=44) | 26 (59.1) | 12 | 18 | 47.0 | 26.9 |
| 2 (n=35) | 32 (91.4) | 18 | 11 | 69.6 | 39.3 |
| ≥3 (n=46) | 36 (78.3) | 17 | 14 | 64.2 | 34.7 |
| DNMT3A | P=0.1208 | P=0.6243 | P=0.7438 | ||
| mut (n=24) | 15 (62.5) | 13 | 13 | 53.0 | 26.5 |
| wt (n=101) | 79 (78.2) | 16 | 12 | 61.4 | 39.1 |
| TET2 | P=1632 | P=0.6365 | P=0.6875 | ||
| mut (n=33) | 28 (84.8) | 17 | 13 | 65.6 | 38.6 |
| wt (n=92) | 66 (71.7) | 15 | 11 | 57.7 | 37.3 |
| IDH1 | P=0.7028 | P=0.8188 | P=0.2503 | ||
| mut (n=10) | 7 (70) | Undefined | Undefined | 51.4 | N/A |
| wt (n=115) | 87 (75.7) | 16 | 12 | 60.5 | 37.6 |
| IDH2 | P=0.7603 | P=0.1423 | P=0.8574 | ||
| mut (n=15) | 12 (80) | 20 | 13 | 86.7 | 40.5 |
| wt (n=110) | 82 (74.5) | 15 | 11 | 55.7 | 37.3 |
| ASXL1 | P=1.0000 | P=0.4425 | P=0.0801 | ||
| mut (n=31) | 24 (77.4) | 16 | 8 | 56.5 | 31.4 |
| wt (n=94) | 70 (74.5) | 16 | 14 | 60.6 | 39.7 |
| RUNX1 | P=1.0000 | P=0.7141 | P=0.4392 | ||
| mut (n=11) | 8 (72.7) | 18 | 18 | 71.6 | 42.9 |
| wt (n=114) | 86 (75.4) | 16 | 12 | 58.7 | 37.5 |
| NPM1 | P=0.4602 | P=0.3479 | P=0.1092 | ||
| mut (n=27) | 22 (81.5) | 19 | 18 | 65.6 | 41.4 |
| wt (n=98) | 72 (73.5) | 15 | 10 | 57.8 | 36.8 |
| CEBPA | P=0.3451 | P=0.2662 | P=0.0994 | ||
| biallelic mut (n=10) | 9 (90) | 15.5 | 9.5 | 60.0 | 20.0 |
| monoallelic mut (n=8) | 7 (87.5) | 19 | 18 | 75.0 | 46.9 |
| wt (n=107) | 78 (72.9) | 16 | 12 | 58.8 | 39.9 |
| FLT3 | P=0.8065 | P=0.2247 | P=0.8653 | ||
| mut (n=29) | 21 (72.4) | 12 | 18 | 46.8 | 32.8 |
| wt (n=96) | 73 (76.0) | 17 | 12 | 63.3 | 37.2 |
| NRAS | P=1.0000 | P=0.7962 | P=0.7377 | ||
| mut (n=22) | 17 (77.3) | 28 | 19 | 58.7 | 52.8 |
| wt (n=103) | 77 (74.8) | 15 | 11 | 60.0 | 34.9 |
| KIT | P=1.0000 | P=0.4152 | P=0.1337 | ||
| mut (n=7) | 5 (71.4) | 14 | 7.5 | 60.0 | N/A |
| wt (n=118) | 89 (75.4) | 16 | 12 | 59.7 | 39.2 |
| TP53 | P=1.0000 | P=0.0657 | P=0.0649 | ||
| mut (n=15) | 11 (73.3) | 10 | 7 | 46.7 | 15.6 |
| wt (n=110) | 83 (75.5) | 18 | 14 | 66.3 | 39.7 |
| Cytogenetics | |||||
| P=0.5641 | P=0.0041 | P=0.0001 | |||
| complex karotypes (n=19) | 13 (68.4) | 9 | 5 | 35.5 | 11.8 |
| others (n=106) | 81 (76.4) | 19 | 15 | 64.6 | 41.5 |
| P=0.7713 | P<0.0001 | P<0.0001 | |||
| -5/5q-, -7/7q- (n=18) | 13 (72.2) | 8.5 | 6 | 27.8 | 5.6 |
| others (n=107) | 81 (75.7) | 19 | 15 | 65.8 | 44.5 |
| P=0.2911 | P=0.3143 | P=0.0004 | |||
| monosomal (n=12) | 11 (91.7) | 13 | 5 | 57.1 | 19.0 |
| others (n=113) | 83 (73.5) | 17 | 14 | 60.1 | 40.3 |
| risk status | P=0.3727 | P=0.0022 | P=0.0041 | ||
| Low-risk (n=12) | 11 (91.7) | Undefined | 15 | 88.9 | 71.1 |
| Intermediate-risk (n=50) | 39 (78.0) | 20 | 15 | 74.0 | 47.9 |
| High-risk (n=63) | 44 (69.8) | 11 | 8 | 44.1 | 25.8 |
Abbreviations: CR: complete remission; OS: overall survival; DFS: disease-free survival; mut: mutated status; wt: wild type.